Published June 1995 | Version v1
Journal article

Radiopharmaceuticals 1994. Nil desperandum

  • 1. Dr. Daniel den Hoed Cancer Center, Dept. of Nuclear Medicine, Rotterdam (Netherlands)

Description

On the basis of the discussions at a symposium held in Duesseldorf and attended by representatives of various interested bodies, European legislation as it affects radiopharmaceuticals is reviewed. Due consideration is given to the new, centralised and decentralised, registration procedures, effective since 1 January 1995. The dossier required to support an application for marketing authorisation is discussed, separate consideration being given to single-photon emitters, therapeutic radio-nuclides and positron-emitting radiopharmaceuticals. The role of the European Pharmacopoiea is also considered. It is concluded that the new, modified procedures for the registration of medicinal products in the European Union may actually inhibit free availability of radiopharmaceuticals within the Community, and that there is a strong case for modification of the European Directives so that radiopharmaceuticals are placed in a separate category to therapeutic drugs, with less stringent registration requirements. (orig.)

Additional details

Publishing Information

Journal Title
European Journal of Nuclear Medicine
Journal Volume
22
Journal Issue
6
Journal Page Range
p. 563-570.
ISSN
0340-6997
CODEN
EJNMD9